A New Xenograft Model of Primary Central Nervous System Lymphoma

Overview

Journal J Neurooncol

Publisher Springer

Date 1999 Oct 26

PMID 10533727

Citations 5

Authors

M Saini

M Bellinzona

W Weichhold

M Samii

Affiliations

Soon will be listed here.

Abstract

The management of primary lymphoma of the central nervous system (PCNSL) remains controversial and patients' outcome dismal. In order to investigate new selective therapeutic strategies in a controlled system, a reproducible model of PCNSL in nude rats was developed and characterized. Human B lymphoma cells (BL2) were implanted in the brain frontal area in New Zealand nude rats through a silastic device sealed to the skull. Fifteen and 30 days post-implantation, animals were sacrificed. An autopsy was performed. Representative brain sections were cut and examined for the presence of lymphoma. Immunohistochemistry was performed for proliferation (MIB1-Ki67), a B-cell marker (L26-CD20), a T-cell marker (UCHL1-CD45RO). The analysis of the brains showed tumor growth in 88% of the rats. No mortality was observed. At autopsy no extracerebral, spinal or cerebellar metastasis were found. Microscopically the brain tumors appeared non-encapsulated, highly vascularized, with a characteristic perivascular and diffuse lymphomatous spread in the parenchyma. Immunohistochemistry showed a marked positivity of the tumor cells for L26. Tumor cells were negative for UCHL1. Mean proliferation rate was 30%. The device was well tolerated and caused no local infection. Controlled studies on PCNSL in animal models are lacking. This PCNSL model in nude rats reproduces the histology and location of human CNS lymphoma. Tumor dimensions are within the resolution limits of CT and MRI and therefore suitable for stereotactic therapy. This model provides a tool to test new chemo and radiotherapeutical strategies in a controlled fashion.

Citing Articles

Cerebellar large B-cell lymphoma: a case report.

Ghannam M, Mansour S, Jumah F, Berry B, Beard A J Med Case Rep. 2018; 12(1):341.

PMID: 30446015 PMC: 6240289. DOI: 10.1186/s13256-018-1880-z.

Advances in the treatment of newly diagnosed primary central nervous system lymphomas.

Qian L, Tomuleasa C, Florian I, Shen J, Florian I, Zdrenghea M Blood Res. 2017; 52(3):159-166.

PMID: 29043230 PMC: 5641507. DOI: 10.5045/br.2017.52.3.159.

Immunomodulatory effects of hemagglutinin- (HA-) modified A20 B-cell lymphoma expanded as a brain tumor on adoptively transferred HA-Specific CD4+ T cells.

Shichkin V, Moriev R ScientificWorldJournal. 2014; 2014:165265.

PMID: 24693228 PMC: 3947776. DOI: 10.1155/2014/165265.

Treatment of central nervous system lymphoma in rats with intraventricular rituximab and serum.

Miyake Y, Okoshi Y, Machino T, Chiba S Int J Hematol. 2010; 92(3):474-80.

PMID: 20820968 DOI: 10.1007/s12185-010-0669-7.

MRI detection of early bone metastases in b16 mouse melanoma models.

Gauvain K, Garbow J, Song S, Hirbe A, Weilbaecher K Clin Exp Metastasis. 2005; 22(5):403-11.

PMID: 16283483 PMC: 2726655. DOI: 10.1007/s10585-005-1264-9.

References

Eby N, Grufferman S, Flannelly C, Schold Jr S, Vogel F, Burger P . Increasing incidence of primary brain lymphoma in the US. Cancer. 1988; 62(11):2461-5. DOI: 10.1002/1097-0142(19881201)62:11<2461::aid-cncr2820621135>3.0.co;2-m. View

Chamberlain M, Levin V . Adjuvant chemotherapy for primary lymphoma of the central nervous system. Arch Neurol. 1990; 47(10):1113-6. DOI: 10.1001/archneur.1990.00530100081017. View

Norris J, Tang L, Sparacio S, Benveniste E . Signal transduction pathways mediating astrocyte IL-6 induction by IL-1 beta and tumor necrosis factor-alpha. J Immunol. 1994; 152(2):841-50. View

Ott R, Brada M, Flower M, Babich J, Cherry S, Deehan B . Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma. Eur J Cancer. 1991; 27(11):1356-61. DOI: 10.1016/0277-5379(91)90009-3. View

Showe L, Moore R, Erikson J, Croce C . MYC oncogene involved in a t(8;22) chromosome translocation is not altered in its putative regulatory regions. Proc Natl Acad Sci U S A. 1987; 84(9):2824-8. PMC: 304752. DOI: 10.1073/pnas.84.9.2824. View

Feiden W, Bise K, Steude U . Diagnosis of primary cerebral lymphoma with particular reference to CT-guided stereotactic biopsy. Virchows Arch A Pathol Anat Histopathol. 1990; 417(1):21-8. DOI: 10.1007/BF01600105. View

Hayakawa T, Takakura K, Abe H, Yoshimoto T, Tanaka R, Sugita K . Primary central nervous system lymphoma in Japan--a retrospective, co-operative study by CNS-Lymphoma Study Group in Japan. J Neurooncol. 1994; 19(3):197-215. DOI: 10.1007/BF01053274. View

Norton A, Isaacson P . Monoclonal antibody L26: an antibody that is reactive with normal and neoplastic B lymphocytes in routinely fixed and paraffin wax embedded tissues. J Clin Pathol. 1987; 40(12):1405-12. PMC: 1141274. DOI: 10.1136/jcp.40.12.1405. View

Hochberg F, Miller D . Primary central nervous system lymphoma. J Neurosurg. 1988; 68(6):835-53. DOI: 10.3171/jns.1988.68.6.0835. View

10.

Bashir R, Okano M, Kleveland K, Pirrucello S, Masih A, Sanger W . SCID/human mouse model of central nervous system lymphoproliferative disease. Lab Invest. 1991; 65(6):702-9. View

11.

List A, Greer J, Cousar J, Johnson D, Greco F, Volsky D . Primary brain lymphoma in the immunocompetent host: relation to Epstein-Barr virus. Mod Pathol. 1990; 3(5):609-12. View

12.

POTMESIL M, Vardeman D, Kozielski A, Mendoza J, STEHLIN J, GIOVANELLA B . Growth inhibition of human cancer metastases by camptothecins in newly developed xenograft models. Cancer Res. 1995; 55(23):5637-41. View

13.

Folkman J . Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285(21):1182-6. DOI: 10.1056/NEJM197111182852108. View

14.

Benveniste E . Inflammatory cytokines within the central nervous system: sources, function, and mechanism of action. Am J Physiol. 1992; 263(1 Pt 1):C1-16. DOI: 10.1152/ajpcell.1992.263.1.C1. View

15.

GOLDSTEIN J, Dickson D, Moser F, Hirschfeld A, Freeman K, Llena J . Primary central nervous system lymphoma in acquired immune deficiency syndrome. A clinical and pathologic study with results of treatment with radiation. Cancer. 1991; 67(11):2756-65. DOI: 10.1002/1097-0142(19910601)67:11<2756::aid-cncr2820671108>3.0.co;2-3. View

16.

Cher L, Glass J, Harsh G, Hochberg F . Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: preliminary results. Neurology. 1996; 46(6):1757-9. DOI: 10.1212/wnl.46.6.1757. View

17.

Bartfai T, Schultzberg M . Cytokines in neuronal cell types. Neurochem Int. 1993; 22(5):435-44. DOI: 10.1016/0197-0186(93)90038-7. View

18.

MacMahon E, Glass J, Hayward S, Mann R, Becker P, CHARACHE P . Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet. 1991; 338(8773):969-73. DOI: 10.1016/0140-6736(91)91837-k. View

19.

Ishii Y, Takami T, Yuasa H, Takei T, Kikuchi K . Two distinct antigen systems in human B lymphocytes: identification of cell surface and intracellular antigens using monoclonal antibodies. Clin Exp Immunol. 1984; 58(1):183-92. PMC: 1576979. View

20.

Freeman C, Shustik C, Brisson M, Meagher-Villemure K, Dylewski I . Primary malignant lymphoma of the central nervous system. Cancer. 1986; 58(5):1106-11. DOI: 10.1002/1097-0142(19860901)58:5<1106::aid-cncr2820580521>3.0.co;2-3. View